Welcome to our dedicated page for Aethlon Medical news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on Aethlon Medical stock.
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California, with news flow centered on development of its investigational Hemopurifier device. Company announcements highlight progress in oncology and infectious disease programs, capital markets activity, and regulatory interactions that shape the outlook for AEMD stock.
Recent news releases describe Aethlon’s ongoing safety, feasibility, and dose-finding oncology trial in Australia, where the Hemopurifier is being evaluated in patients with solid tumors who have not responded to anti-PD-1 therapies. Updates have covered early observations on extracellular vesicles, microRNAs, and lymphocyte counts in initial cohorts, along with protocol amendments and site activity. The company also reports collaborations in Long COVID research, including preclinical data showing that its GNA affinity resin binds extracellular vesicles in Long COVID plasma and depletes EV-associated microRNAs linked to inflammatory pathways.
Investors following AEMD news will also see regular disclosures on financing transactions, such as public offerings and private placements of common stock, pre-funded warrants, and common stock purchase warrants. These items detail gross proceeds, warrant terms, and intended uses of capital for clinical trials, research and development, and working capital. Additional coverage includes patent issuances related to Long COVID and COVID-19-associated coagulopathy, Nasdaq listing compliance updates, and scheduling of quarterly financial results and conference calls.
This news page aggregates Aethlon Medical’s press releases and related coverage so readers can review clinical updates, scientific publications, financing events, and regulatory milestones in one place. For those tracking AEMD, it offers a structured view of how the company communicates progress on the Hemopurifier and its broader development strategy over time.
Aethlon Medical, Inc. (Nasdaq: AEMD) will release its third quarter fiscal year 2021 financial results on February 10, 2021, at 4:15 p.m. EST. Management will host a conference call at 4:30 p.m. EST to review the results and discuss corporate developments. The Hemopurifier®, Aethlon's immunotherapeutic device, targets cancer and viral infections and has received FDA Breakthrough Device designations. Notably, it is currently being evaluated in a feasibility study for treating COVID-19 patients. Interested parties can register or dial in for the call.
Aethlon Medical, Inc. (Nasdaq: AEMD) announced key executive appointments on January 6, 2021, enhancing its leadership team. Guy Cipriani joins as Senior Vice President and Chief Business Officer, focusing on business development and fundraising, while Dr. Steven LaRosa becomes Chief Medical Officer, overseeing clinical operations for the Hemopurifier®. Cipriani's extensive background includes significant roles at Microbion and Cardiome Pharma, while LaRosa has clinical experience in infectious diseases. The Hemopurifier, an FDA-designated 'Breakthrough Device,' aims to address cancer and severe viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the virtual H.C. Wainwright BioConnect 2021 Conference from Jan. 11-14, 2021. A webcast of their presentation will be available on-demand starting at 6:00 a.m. EDT on Jan. 11, accessible through their website. The company focuses on addressing unmet needs in viral diseases and cancer with its Hemopurifier device, designated as a Breakthrough Device by the FDA. It aims to combat cancer by depleting tumor-derived exosomes and has received FDA approval for an Early Feasibility Study for COVID-19 treatment.
Aethlon Medical, Inc. (AEMD) has announced the treatment of its first patient in a first-in-human Early Feasibility Study (EFS) using the HEMOPURIFIER® for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck at UPMC Hillman Cancer Center, Pittsburgh. The trial aims to assess the safety of the HEMOPURIFIER® and its potential to improve the efficacy of pembrolizumab (KEYTRUDA®) by reducing cancer-associated exosomes. This represents a crucial step in addressing unmet needs in cancer treatment, especially regarding immune suppression caused by tumor-derived exosomes.
Aethlon Medical, Inc. (Nasdaq: AEMD) appointed Dr. Charles J. Fisher, Jr. as CEO effective October 30, 2020, succeeding Dr. Timothy Rodell, who will transition to a consultancy role. Dr. Fisher has significant experience, including leadership roles at Eli Lilly and Abbott Laboratories, and is expected to enhance Aethlon's product development, particularly the Hemopurifier, aimed at treating life-threatening viral infections and cancer. The company is now initiating clinical trials for the Hemopurifier in patients with COVID-19 and advanced cancer.
Aethlon Medical, Inc. (AEMD) reported its financial results for the second quarter ending September 30, 2020. The company has approximately $14.5 million in cash and reported a net loss of about $1.77 million, up from $1.71 million year-over-year. Operating expenses increased by 4.1% to $1.77 million, driven by higher general and administrative costs.
The company is advancing its Hemopurifier device through FDA-approved clinical trials for cancer and COVID-19 treatments. The first trial is open for enrollment in patients with advanced head and neck cancer.
Aethlon Medical, Inc. (AEMD) will release its financial results for Q2 FY2021 on October 28, 2020, at 4:15 PM ET. The results will cover the period ending September 30, 2020. A conference call will follow at 4:30 PM ET, allowing management to discuss the outcomes and recent developments. Interested participants can register online for the conference call or dial in using the toll-free or international numbers provided. Aethlon focuses on unmet health needs, particularly with its Aethlon Hemopurifier®, a device for treating cancer and viral infections.
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical device technology firm, will be presenting at the HC Wainwright 22nd Annual Global Investment Conference on Monday, Sept. 14, 2020, at 2:00 p.m. EDT. The presentation will be led by CEO Timothy C. Rodell and will be available for replay for 90 days post-presentation. Aethlon’s primary focus is the Hemopurifier®, a breakthrough immunotherapeutic device targeting cancer and life-threatening viral infections. The Hemopurifier aims to reduce tumor-derived exosomes that contribute to immune suppression and metastasis.
Aethlon Medical, Inc. (Nasdaq: AEMD) will present at the LD Micro 500 virtual investor conference on September 3, 2020, at 11:40 AM PT. CEO Timothy C. Rodell, MD, will also hold one-on-one meetings with investors throughout the day. The presentation will be accessible live and later as a replay on Aethlon's website. The LD Micro 500 runs from September 1-4, featuring 500 micro-cap companies. Aethlon's Hemopurifier® is a breakthrough device targeting cancer and viral infections, focusing on depleting tumor-derived exosomes.
Aethlon Medical, Inc. (AEMD) announced its financial results for Q1 2020, reporting a net loss of approximately $1.4 million, reduced from $2.1 million in Q1 2019. Operating expenses decreased by 12% to $1.4 million, attributed to lower payroll and professional fees. Aethlon continues developing its Hemopurifier®, now entering clinical trials for advanced cancer and SARS-CoV-2 treatment. The company received a $3.5 million NIH grant to support exosome research. As of June 30, 2020, it reported a cash balance of $15.7 million.
FAQ
What is the current stock price of Aethlon Medical (AEMD)?
What is the market cap of Aethlon Medical (AEMD)?
